The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1618-7601
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England ; day:9 ; month:3 ; year:2018 ; pages:1-10
The European journal of health economics ; (9.3.2018), 1-10
- Creator
- Contributor
-
Hertel, Nadine
Ellis, John
Morais, Edith
Johnson, Helen
Philips, Zoe
Roskell, Neil
Walker, Andrew
Lee, Dawn
SpringerLink (Online service)
- DOI
-
10.1007/s10198-018-0964-4
- URN
-
urn:nbn:de:1111-2018051328840
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Meng, Yang
- Hertel, Nadine
- Ellis, John
- Morais, Edith
- Johnson, Helen
- Philips, Zoe
- Roskell, Neil
- Walker, Andrew
- Lee, Dawn
- SpringerLink (Online service)
Other Objects (12)
Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
Effectiveness and cost-effectiveness of combination therapy versus monotherapy in malignant melanoma
Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Successful Conversion Surgery for Stage IV Gastric Cancer after Nivolumab Monotherapy as Third-Line Chemotherapy
Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma